DRUG
Macupatide
Administered SC
A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
Status
Recruiting
Phase
Phase 2
Enrollment
400
Locations
40
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will last about 64 weeks.
Interventions
Treatment arms and agents.
DRUG
Eloralintide
Administered SC
DRUG
Placebo
Administered SC
Timeline
From registration to results.
First posted
May 15, 2026
Study start
May 15, 2026
Primary completion
Sep 2027
Study completion
Feb 2028
Results posted
Not reported
Registry updated
Jun 24, 2026
Outcomes
What the study measures.
Primary outcomes
Percent Change from Baseline in Body Weight
Time frame · Baseline, Week 36
Secondary outcomes
Percent Change from Baseline in Body Weight
Time frame · Baseline, Week 48
Change from Baseline in Body Weight
Time frame · Baseline, Week 36
Percentage of Participants who Achieve ≥5% Body Weight Reduction
Time frame · Week 36
Percentage of Participants who Achieve ≥10% Body Weight Reduction
Time frame · Week 36
Change from Baseline in Body Mass Index (BMI)
Time frame · Baseline, Week 36
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: * See Master Protocol CWMM (NCT06143956) for inclusion criteria Exclusion Criteria: In addition to exclusion criteria in Master Protocol CWMM (NCT06143956): * Have type 1 diabetes or type 2 diabetes * Have an ongoing history of bradyarrhythmia and/or sinus bradycardia * Have an elevated resting pulse rate (greater than 100 bpm) or reduced resting pulse rate (less than 60 bpm) * Have a history of acute or chronic pancreatitis * All concomitant medications should be at a stable dose for at least 3 months prior to screening
Study locations
40 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
The Institute for Liver Health II dba Arizona Clinical Trials - Mesa
Chandler, Arizona, United States
Headlands Research - Scottsdale
Scottsdale, Arizona, United States
The Institute for Liver Health II dba Arizona Liver Health-Tucson
Tucson, Arizona, United States
NorCal Medical Research, Inc
Greenbrae, California, United States
Velocity Clinical Research, Huntington Park
Huntington Park, California, United States
Peninsula Research Associates
Rolling Hills Estates, California, United States
Diablo Clinical Research, Inc.
Walnut Creek, California, United States
Stamford Therapeutics Consortium
Stamford, Connecticut, United States
New Horizon Research Center
Miami, Florida, United States
Indago Research & Health Center, Inc
Miami Lakes, Florida, United States
Suncoast Clinical Research, Inc.
New Port Richey, Florida, United States
Charter Research - Winter Park
Orlando, Florida, United States
Charter Research - Lady Lake
The Villages, Florida, United States
Medical Research Partners
Ammon, Idaho, United States
Great Lakes Clinical Trials - Ravenswood
Chicago, Illinois, United States
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas, United States
Monroe Biomedical Research - Louisville
Louisville, Kentucky, United States
Knownwell
Needham, Massachusetts, United States
Lucida Clinical Trials
New Bedford, Massachusetts, United States
Headlands Research - Detroit
Southfield, Michigan, United States
Arcturus Healthcare , PLC, Troy Internal Medicine Research Division
Troy, Michigan, United States
StudyMetrix Research
City of Saint Peters, Missouri, United States
Clinvest Headlands Llc
Springfield, Missouri, United States
Las Vegas Medical Research
Las Vegas, Nevada, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Eloralintide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 1
Not yet recruiting
56
2026-07
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
1,481
2026-07
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly · Obesity · Overweight
Phase 2
Active, not recruiting
367
2026-07
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
Eli Lilly · Obesity · Overweight
Phase 2
Recruiting
200
2026-07
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Eli Lilly · Overweight · Obesity
Phase 3
Recruiting
1,035
2026-07
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Eli Lilly · Obesity · Overweight
Phase 3
Recruiting
1,980
2026-07
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
Eli Lilly · Osteoarthritis · Overweight or Obesity
Phase 3
Recruiting
900
2026-07
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
Eli Lilly · Sleep Apnea, Obstructive · Obesity
Phase 3
Recruiting
800
2026-07
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.